Physician

Nandan Thirunahari, M.D

According to 2025 Medicare claims, Nandan Thirunahari, M.D (NPI: 1437462835) practices advanced heart failure and transplant cardiology in the Trenton-Princeton, NJ market, with the plurality of this provider's patient population coming from Mercer, NJ. This provider's primary affiliated billing organization is CLINICAL HEALTH CARE ASSOCIATES OF NEW JERSEY, P.C. (NPI: 1447260435; TIN: 232865181) and primary practice location at 08536-1913. Thirunahari is affiliated with the AtlantiCare Health Solutions, Inc. (ACO ID: A4516), participating under the MSSP model.

Thirunahari's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,001 traditional Medicare patients, billed 3,079 HCPCS/CPT codes, and received $239,423 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 4,129 prescription claims across 642 beneficiaries totaling $774,830 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 30 claims. Open Payments data shows 81 records totaling $5,978. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $14,101 to $239,423. Similarly, Part D prescription costs have risen steadily, from $467 to $774,830. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $14,517 to $42,065.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	79	164	$14,101
2016	711	1,848	$141,578
2017	849	2,547	$151,987
2018	911	2,813	$169,828
2019	978	2,574	$198,962
2020	894	2,776	$234,123
2021	952	2,947	$255,098
2022	978	3,150	$237,097
2023	998	2,981	$223,360
2024	1,001	3,079	$239,423

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	26	$467
2016	72	394	$17,244
2017	133	1,092	$81,774
2018	297	2,410	$233,565
2019	362	2,106	$246,334
2020	271	1,467	$166,188
2021	333	2,043	$221,950
2022	490	3,238	$443,031
2023	579	4,135	$863,264
2024	642	4,129	$774,830

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	24	$727
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	66	$4,606
2022	N/R	11	$25,134
2023	N/R	30	$42,065
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	227	234	$136
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	292	303	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	486	884	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	130	216	$94
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	412	556	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	207	14,033	$261,711
Entresto	Sacubitril/Valsartan	116	6,660	$143,273
Camzyos	Mavacamten	13	430	$112,740
Farxiga	Dapagliflozin Propanediol	50	3,106	$52,109
Xarelto	Rivaroxaban	23	1,770	$31,132

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	80	$1,413	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$4,565	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nandan Thirunahari, M.D?

Tedicare shows public-source Medicare data for Nandan Thirunahari, M.D (NPI 1437462835), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nandan Thirunahari, M.D have ACO affiliation data?

Nandan Thirunahari, M.D is shown with ACO affiliation data for AtlantiCare Health Solutions, Inc. (MSSP, ACO ID A4516).

What billing organization is linked to Nandan Thirunahari, M.D?

Nandan Thirunahari, M.D is linked to CLINICAL HEALTH CARE ASSOCIATES OF NEW JERSEY, P.C. (billing NPI 1447260435) in the available physician profile data.

Does Nandan Thirunahari, M.D have Open Payments data?

Nandan Thirunahari, M.D has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.